Home›Stock Screener›Indrayani Biotech›Financial Statements

Indrayani Biotech Complete Financial Statements

6 Years of Data
2025 - 2020

In FY2025, Indrayani Biotech (INDRANIB) reported revenue ₹38 Cr, net profit ₹1 Cr and EPS ₹0.09, with a net profit margin of 2.6% and ROE of 1.0%. Full financial statements from FY2020 to FY2025 (6 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review INDRANIB earnings valuation to evaluate earnings-based valuation against sector peers.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 2.63% 2025 data
EBITDA Margin 10.53% 2025 data
Operating Margin 7.00% 2025 data
Return on Assets 0.37% 2025 data
Return on Equity 1.00% 2025 data

Balance Sheet Ratios

Current Ratio 2.70 2025 data
Equity Ratio 37.31% 2025 data
Asset Turnover 0.14 2025 data

INDRANIB Revenue, Net Profit & EBITDA — Year-on-Year Growth

INDRANIB YoY (Sept 2024 vs Sept 2025) — revenue +22.6%, EBITDA -20.0%, expenses +30.8%. For live price, earnings ratios and company overview, see Indrayani Biotech screener.

Revenue Growth
+22.6%
Year-over-Year
EBITDA Growth
-20.0%
Year-over-Year
Expense Growth
+30.8%
Year-over-Year
Assets Growth
+14.5%
Year-over-Year
Equity Growth
+31.6%
Year-over-Year
Operating Cash Flow Growth
+76.7%
Year-over-Year
Investing Cash Flow Growth
+256.3%
Year-over-Year
Financing Cash Flow Growth
-140.9%
Year-over-Year

INDRANIB Income Statement — Revenue, EBITDA & Net Profit

Indrayani Biotech revenue ₹38 Cr, EBITDA ₹4 Cr, net profit ₹1 Cr, EPS ₹0.09 (2025) — net profit margin 2.6%. Explore INDRANIB intrinsic value to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 Mar 2024 Jun 2024 Dec 2024 Sept 2023 Mar 2023 Jun 2023 Dec 2023 Sept 2022 Mar 2022 Jun 2022 Dec 2022 Sept 2021 Mar 2021 Jun 2021 Dec 2021 Sept 2020 Mar 2020 Jun 2020 Dec 2020
Revenue 38 53 30 36 31 45 32 17 41 51 42 39 44 17 26 46 15 7 14 15 5 14 4 6
Expenses 34 54 27 32 26 34 26 14 33 46 40 36 37 15 23 41 13 10 13 13 4 14 9 7
EBITDA 4 0 3 4 5 11 6 3 7 5 3 4 7 2 3 5 2 -2 1 2 1 1 -5 -1
Operating Profit Margin % 7.00% -6.00% 7.00% 8.00% 17.00% 23.00% 19.00% 17.00% 18.00% 6.00% 6.00% 9.00% 12.00% 13.00% 12.00% 12.00% 11.00% -36.00% 7.00% 12.00% 13.00% 6.00% -159.00% -20.00%
Depreciation 1 10 1 1 3 1 4 2 1 1 1 1 1 0 1 1 0 0 0 0 0 0 0 0
Interest 2 -2 2 3 1 6 1 1 1 2 2 1 1 0 1 1 1 1 0 1 0 0 0 0
Profit Before Tax 1 -8 0 0 1 5 1 0 6 2 0 1 5 2 2 3 1 -3 1 1 0 0 -5 -2
Tax 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Net Profit 1 -9 0 0 1 5 1 0 6 1 0 1 5 2 2 3 1 -3 1 1 0 0 -5 -2
Earnings Per Share (₹) 0.09 -1.42 0.03 0.01 0.13 0.58 0.10 0.05 0.89 0.32 -0.06 0.22 1.47 0.47 0.52 0.72 0.30 -0.92 0.20 0.33 0.03 0.08 -1.57 -0.51

INDRANIB Balance Sheet — Assets, Liabilities & Shareholders' Equity

INDRANIB total assets ₹268 Cr, total equity ₹100 Cr, total liabilities ₹ Cr (2025) — ROE 1.0%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022 2021 2020
ASSETS
Total Assets 268 234 156 51 40 52
Current Assets 178 145 78 19 9 19
Fixed Assets 58 62 58 17 15 17
Capital Work in Progress 26 20 14 13 14 14
Investments 0 0 0 0 0 0
Other Assets 184 151 85 22 11 21
LIABILITIES
Total Liabilities
Current Liabilities 66 71 36 7 8 7
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 100 76 48 25 20 31
Share Capital 46 46 44 34 34 4
Reserves & Surplus 24 18 10 -10 -15 -3

INDRANIB Cash Flow Statement — Operating, Investing & Financing

Indrayani Biotech operating cash flow ₹-7 Cr, investing ₹25 Cr, financing ₹-18 Cr, net cash flow ₹0 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020
Operating Activities -7 -30 16 4 0 6
Investing Activities 25 -16 -47 -1 -1 -4
Financing Activities -18 44 33 -3 0 -1
Net Cash Flow 0 -3 2 1 -1 1